Sarepta: Disclosure Of An Elevidys Patient's Death Creates Market Uncertainty
Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...
Sarepta plunges after death linked to Elevidys (update)
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
Is This Stock a Buy After a Massive 20% Drop in 1 Day?
Things are going from bad to worse for Sarepta Therapeutics (NASDAQ: SRPT), a biotech focusing on gene therapies. The company ...
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Fierce Pharma7d
Sarepta reports one death after patient received DMD gene therapy Elevidys
One patient with Duchenne muscular dystrophy (DMD) has passed away following treatment with Sarepta Therapeutics’ gene therapy Elevidys, the biotech ...
Zacks.com on MSN6d
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Shares of Sarepta Therapeutics SRPT plunged more than 20% yesterday after the company reported the death of a patient after treatment with Elevidys, its one-shot gene therapy for Duchenne muscular ...
GEN - Genetic Engineering and Biotechnology News7d
DMD Patient Dies After Treatment with Sarepta Gene Therapy
The patient, whom Sarepta described as a young man and later told news outlets was 16 years old, suffered acute liver failure ...
GEN - Genetic Engineering and Biotechnology News2d
StockWatch: After DMD Patient Death, Analysts Still Bullish on Sarepta
Why didn’t analysts share the same fear that gripped investors about Sarepta stock? One reason is the known risk of acute liver injury associated with adeno-associated virus vector (AAV)-based gene ...
American Association of Individual Investors9d
Which Is a Better Investment, PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. Stock?
Learn more about whether PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...
Nasdaq6d
SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
Elevidys has been developed by Sarepta in partnership with pharma giant Roche RHHBY. SRPT and RHHBY entered into a licensing agreement in 2019 to develop Elevidys. Per the agreement, Roche has ...